Welcome!

News Feed Item

Stockholder Rights Plan, Quarterly Results, Clinical Trial Results, Purchase Agreements, and New Contracts - Analyst Notes on Allergan, Gilead, Pfizer, Actavis and Express Scripts

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 25, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Allergan, Inc. (NYSE: AGN), Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT) and Express Scripts Holding Company (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1586-100free.

--
Allergan, Inc. Analyst Notes
On April 22, 2014, Allergan, Inc. (Allergan) announced that its Board of Directors has unanimously adopted a one-year stockholder rights plan, effective on the day of the announcement, and has declared a dividend distribution of one preferred share purchase right on each outstanding share of the Company's common stock. The Company informed that under the plan, stockholders of record at the close of business on May 8, 2014 will receive one right for each share of Allergan common stock held on that date. Allergan informed that the plan is expected to expire on April 22, 2015. The full analyst notes on Allergan are available to download free of charge at:

http://www.analystsreview.com/1586-AGN-25Apr2014.pdf

--
Gilead Sciences, Inc. Analyst Notes
On April 22, 2014, Gilead Sciences, Inc. (Gilead) reported Q1 2014 financial results. During the quarter, the Company's total revenues increased to c. $5 billion from $2.5 billion in Q1 2013. Q1 2014 net income attributable to Gilead was $2.2 billion, or $1.33 per diluted share, compared to $722.2 million, or $0.43 per diluted share, in Q1 2013. Q1 2014 non-GAAP net income attributable to the Company was $2.5 billion, or $1.48 per diluted share, compared to $801.9 million, or $0.48 per diluted share, in Q1 2013. The Company reiterated its full-year 2014 guidance with net product sales expected to range from $11.3 billion - $11.5 billion. The full analyst notes on Gilead are available to download free of charge at:

http://www.analystsreview.com/1586-GILD-25Apr2014.pdf

--
Pfizer Inc. Analyst Notes
On April 22, 2014, Pfizer Inc. (Pfizer) announced top-line results from OPT Pivotal #1, and OPT Pivotal #2 Phase 3 trials from the oral treatment psoriasis trials (OPT) Program, evaluating the efficacy and safety of tofacitinib. The Company informed that OPT Pivotal #1 and OPT Pivotal #2 studies demonstrated that tofacitinib, as a 5mg or a 10mg dose taken as a pill twice-daily, met the primary efficacy endpoints of statistically significant superiority over placebo at Week 16 in the proportion of subjects achieving a Physician's Global Assessment response of "clear" or "almost clear," and the proportion of subjects achieving at least a 75% reduction in Psoriasis Area and Severity Index. The Company informed that it intends to submit a supplemental New Drug Application to the U.S. Food and Drug Administration for the approval of tofacitinib 5mg and 10mg twice-daily for treating adults with moderate-to-severe chronic plaque psoriasis by early 2015. The full analyst notes on Pfizer are available to download free of charge at:

http://www.analystsreview.com/1586-PFE-25Apr2014.pdf

--
Actavis plc Analyst Notes
On April 17, 2014, Actavis plc (Actavis) announced that it has entered into agreements with Akorn, Inc. (Akorn) and Hi-Tech Pharmacal Co. (Hi-Tech Pharmacal), in order to purchase four currently marketed products and one product under development for cash consideration. Actavis informed that the closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech Pharmacal. "The acquisition of these products will complement our expanding portfolio of topical and ophthalmic generic products, and further strengthen our position as a leader in developing and marketing the complex, high-barrier products that provide enhanced value," commented Siggi Olafsson, President of Actavis. The full analyst notes on Actavis are available to download free of charge at:

http://www.analystsreview.com/1586-ACT-25Apr2014.pdf

--
Express Scripts Holding Company Analyst Notes
On April 18, 2014, Express Scripts Holding Company (Express Scripts) reported that the U.S. Department of Defense has awarded the Company administration of the TRICARE Pharmacy Program, Fourth Generation (TPharm4) contract serving approximately 10 million beneficiaries. Express Scripts informed that the seven-year contract includes administering a retail pharmacy network, operating the TRICARE Mail Order Pharmacy and providing specialty pharmacy services, effective May 1, 2015. The full analyst notes on Express Scripts are available to download free of charge at:

http://www.analystsreview.com/1586-ESRX-25Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


http://AnalystsReview.com

 

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that HTBase will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. HTBase (Gartner 2016 Cool Vendor) delivers a Composable IT infrastructure solution architected for agility and increased efficiency. It turns compute, storage, and fabric into fluid pools of resources that are easily composed and re-composed to meet each application’s needs. With HTBase, companies can quickly prov...
SYS-CON Events announced today that Infranics will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Since 2000, Infranics has developed SysMaster Suite, which is required for the stable and efficient management of ICT infrastructure. The ICT management solution developed and provided by Infranics continues to add intelligence to the ICT infrastructure through the IMC (Infra Management Cycle) based on mathemat...
SYS-CON Events announced today that Cloudistics, an on-premises cloud computing company, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Cloudistics delivers a complete public cloud experience with composable on-premises infrastructures to medium and large enterprises. Its software-defined technology natively converges network, storage, compute, virtualization, and management into a ...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
Building custom add-ons does not need to be limited to the ideas you see on a marketplace. In his session at 20th Cloud Expo, Sukhbir Dhillon, CEO and founder of Addteq, will go over some adventures they faced in developing integrations using Atlassian SDK and other technologies/platforms and how it has enabled development teams to experiment with newer paradigms like Serverless and newer features of Atlassian SDKs. In this presentation, you will be taken on a journey of Add-On and Integration ...
There are 66 million network cameras capturing terabytes of data. How did factories in Japan improve physical security at the facilities and improve employee productivity? Edge Computing reduces possible kilobytes of data collected per second to only a few kilobytes of data transmitted to the public cloud every day. Data is aggregated and analyzed close to sensors so only intelligent results need to be transmitted to the cloud. Non-essential data is recycled to optimize storage.
"I think that everyone recognizes that for IoT to really realize its full potential and value that it is about creating ecosystems and marketplaces and that no single vendor is able to support what is required," explained Esmeralda Swartz, VP, Marketing Enterprise and Cloud at Ericsson, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership abi...
The essence of cloud computing is that all consumable IT resources are delivered as services. In his session at 15th Cloud Expo, Yung Chou, Technology Evangelist at Microsoft, demonstrated the concepts and implementations of two important cloud computing deliveries: Infrastructure as a Service (IaaS) and Platform as a Service (PaaS). He discussed from business and technical viewpoints what exactly they are, why we care, how they are different and in what ways, and the strategies for IT to transi...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service.
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
SYS-CON Events announced today that Outlyer, a monitoring service for DevOps and operations teams, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outlyer is a monitoring service for DevOps and Operations teams running Cloud, SaaS, Microservices and IoT deployments. Designed for today's dynamic environments that need beyond cloud-scale monitoring, we make monitoring effortless so you ...
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...